Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 38,967 shares, an increase of 196.4% from the March 15th total of 13,145 shares. Based on an average daily volume of 41,763 shares, the short-interest ratio is currently 0.9 days. Currently, 3.0% of the shares of the stock are sold short.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Up 2.2%

Shares of Sonoma Pharmaceuticals stock traded up $0.05 during trading hours on Monday, reaching $2.33. 8,195 shares of the company’s stock were exchanged, compared to its average volume of 22,803. The business has a fifty day moving average of $2.61 and a two-hundred day moving average of $3.28. The company has a market capitalization of $4.03 million, a P/E ratio of -1.14 and a beta of 1.76. Sonoma Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Tuesday, February 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The business had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $5.47 million. As a group, research analysts predict that Sonoma Pharmaceuticals will post -0.67 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.